CG Oncology, Inc. (CGON) Ownership
CGON ownership summary
as of October 18, 2026- Institutions
- 113.6% of shares outstanding
- Insiders
- 0.23% of shares outstanding
- Shares outstanding
- 88.6M
- Float
- 68.3M shares available to trade
- Short interest
- 11.99% 10.4M shares short
- Days to cover
- 10.75 short interest down 7.2% vs prior month
- Institutions 113.57%
- Insiders 0.23%
CGON top institutional holders
1 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Caption Management, LLC | 0.55% | 484K | $29.0M | +105,981 (+28.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 1, 1 holders added 106K shares and 0 cut 0.
CGON top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard Health Care Inv | 3.23% | 2.9M | $171.2M | −72,424 (−2.5%) | June 30, 2026 |
| 2 | T. Rowe Price Capital Appreciation | 2.72% | 2.4M | $144.3M | — | August 31, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 2.69% | 2.4M | $143.0M | −3,121 (−0.1%) | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 2.16% | 1.9M | $114.4M | −22,016 (−1.1%) | September 30, 2026 |
| 5 | Vanguard Small Cap Index | 1.95% | 1.7M | $103.3M | +2,032 (+0.1%) | August 31, 2026 |
| 6 | State Street® SPDR® S&P® Biotech ETF | 1.75% | 1.6M | $92.9M | −29,550 (−1.9%) | September 30, 2026 |
| 7 | T. Rowe Price New Horizons | 1.17% | 1.0M | $62.0M | −42,359 (−3.9%) | August 31, 2026 |
| 8 | Fidelity Small Cap Index | 0.91% | 807K | $48.3M | +6,574 (+0.8%) | July 31, 2026 |
| 9 | Fidelity Small Cap Growth | 0.90% | 797K | $47.7M | — | July 31, 2026 |
| 10 | T. Rowe Price Mid-Cap Growth | 0.84% | 744K | $44.5M | −322 (−0.0%) | August 31, 2026 |
| 11 | T. Rowe Price Integrated US Sm Gr Eq | 0.81% | 714K | $42.7M | — | August 31, 2026 |
| 12 | iShares Russell 2000 Growth ETF | 0.78% | 690K | $41.3M | −874 (−0.1%) | September 30, 2026 |
| 13 | JNL/T. Rowe Price Capital Appreciation A | 0.66% | 586K | $35.1M | +16,050 (+2.8%) | June 30, 2026 |
| 14 | American Century Small Cap Growth Inv | 0.63% | 554K | $33.2M | +554,416 (0.0%) | June 30, 2026 |
| 15 | Worldwide Healthcare Ord | 0.62% | 550K | $32.9M | +25,833 (+4.9%) | June 30, 2026 |
| 16 | Vanguard MStar Small Cap Value Index | 0.62% | 548K | $32.8M | +414 (+0.1%) | August 31, 2026 |
| 17 | Vanguard MStar Small Cap Growth Indx Inv | 0.56% | 494K | $29.5M | −3,857 (−0.8%) | August 31, 2026 |
| 18 | Fidelity Small Cap Growth K6 | 0.54% | 480K | $28.7M | — | July 31, 2026 |
| 19 | Fidelity Select Health Care | 0.52% | 460K | $27.5M | — | August 31, 2026 |
| 20 | iShares Biotechnology ETF | 0.52% | 457K | $27.4M | −3,464 (−0.8%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
CGON insider transactions
latest 15| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-17 | James Mulay | Sell | $73.01 | 15,600 | $1.1M |
| 2026-03-16 | James Mulay | Sell | $63.50 | 1,964 | $124,714 |
| 2026-01-09 | James Mulay | Sell | $52.47 | 11,145 | $584,778 |
| 2025-11-17 | Leonard E Post | Sell | $41.43 | 1,000 | $41,430 |
| 2025-10-09 | James Mulay | Sell | $43.99 | 5,903 | $259,673 |
| 2025-09-30 | Leonard E Post | Sell | $40.09 | 5,000 | $200,450 |
| 2025-09-29 | James Mulay | Sell | $39.19 | 12,755 | $499,868 |
| 2025-09-19 | James Mulay | Sell | $38.99 | 3,574 | $139,350 |
| 2025-09-18 | James Mulay | Sell | $39.01 | 19,112 | $745,559 |
| 2025-09-15 | Leonard E Post | Sell | $35.10 | 1,000 | $35,100 |
| 2025-09-11 | Brian Guan-Chyun Liu | Buy | $33.00 | 1,515,151 | $50.0M |
| 2025-09-05 | James Mulay | Sell | $31.53 | 27,015 | $851,783 |
| 2025-09-03 | Hong Fang Song | Sell | $27.80 | 100,000 | $2.8M |
| 2025-07-17 | Leonard E. Post | Sell | $28.00 | 2,000 | $56,000 |
| 2025-04-28 | Leonard E. Post | Sell | $30.76 | 1,000 | $30,760 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
CGON shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns CGON
Institutional investors own 113.6% of CG Oncology's shares and insiders 0.23%. The largest holder is Caption Management, LLC with 0.55% of the shares (484K), as of June 30, 2026. Among the top 1 institutions, 1 added shares and 0 reduced their stake in the latest filings. Short interest is 11.99% of the float, or 10.75 days of average trading volume. The share count rose 16.0% since 2022.
Related: CGON analyst forecast, CGON key metrics. See the CGON stock overview for the latest quote and news.
CGON ownership FAQ
Who owns the most CG Oncology stock?
The largest shareholders of CG Oncology are Caption Management, LLC (0.55%).
What percentage of CG Oncology is owned by institutions?
Institutions hold 113.6% of CG Oncology's shares outstanding; insiders hold 0.23%.
Which funds own CG Oncology?
The largest fund holders of CG Oncology are Vanguard Health Care Inv (3.23%), T. Rowe Price Capital Appreciation (2.72%), Vanguard MStar Total Stk Mkt Idx Invest (2.69%), iShares Russell 2000 ETF (2.16%), Vanguard Small Cap Index (1.95%).
What is CG Oncology's short interest?
10.4M shares of CG Oncology were sold short, 11.99% of the float; at the average daily volume it would take 10.75 days to cover.
Are insiders buying or selling CG Oncology?
Of the latest 15 reported insider transactions in CG Oncology (since April 28, 2025), 1 were purchases and 14 were sales.
How many shares of CG Oncology are outstanding?
CG Oncology has 88.6M shares outstanding, of which 68.3M are in the public float.